Artia Global Partners LP purchased a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) in the fourth quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 45,000 shares of the company’s stock, valued at approximately $5,375,000. Neurocrine Biosciences accounts for approximately […]
Neurocrine Biosciences (NASDAQ:NBIX – Get Rating) had its price target cut by stock analysts at Stifel Nicolaus from $145.00 to $125.00 in a report released on Tuesday, The Fly reports. Stifel Nicolaus’ price target would suggest a potential upside of 34.12% from the stock’s previous close. NBIX has been the topic of several other research […]
BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) in the fourth quarter, according to the company in its most recent Form 13F filing with the SEC. The fund acquired 4,414 shares of the company’s stock, valued at approximately $527,000. A number of other institutional investors […]
Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) has been assigned a consensus rating of “Moderate Buy” from the twenty-one ratings firms that are currently covering the stock, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation, ten have assigned a buy recommendation and one has given a strong buy recommendation […]
Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX – Get Rating) have received a consensus rating of “Moderate Buy” from the twenty-one ratings firms that are covering the firm, Marketbeat.com reports. Three investment analysts have rated the stock with a hold recommendation, ten have given a buy recommendation and one has assigned a strong buy recommendation to […]